ERBB2 and breast cancer: Since the clinical application of the humanized anti-HER2 antibody, trastuzumab, as a clinical anticancer agent for HER2-positive breast cancer, selection of trastuzumab treatment has been based on the HER2 status of primary tumors [16], [25], [26].